<DOC>
	<DOC>NCT00964457</DOC>
	<brief_summary>response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer</brief_summary>
	<brief_title>Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients</brief_title>
	<detailed_description>Dynamic MRI will be used to monitor the effect of the treatment and will be compared to pathologic results.</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>advanced rectum cancer prior radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>cetuximab</keyword>
	<keyword>rectum cancer</keyword>
	<keyword>radiation</keyword>
	<keyword>MRI</keyword>
</DOC>